U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905287) titled 'Clarify HPP: Disease Burden of HPP Patients in China' on Sept. 07.
Brief Summary: A multi-Center, prospective, observational study of the disease burden of Hypophosphatasia (HPP) patients in China. The study aims to prospectively collect real-world outcome data on HPP, including QoL, clinical manifestations, patient-reported outcomes (PROs) among Chinese HPP patients.
Study Start Date: Sept. 26
Study Type: OBSERVATIONAL
Condition:
Hypophosphatasia (HPP)
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....